Cada tres segundos alguien muere de sepsis en el mundo

1.06. Programas de intervención



  1. Approaches to Modifying the Behavior of Clinicians Who Are Noncompliant With Antimicrobial Stewardship Program Guidelines. Goldstein EJ, Goff DA, Reeve W, Naumovski S, Epson E, Zenilman J, Kaye KS, File TM Jr. Clin Infect Dis. 2016 Aug 15;63(4):532-8. [PubMed]
  2. Implementing an Antibiotic Stewardship Program: Guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America. Barlam TF, Cosgrove SE, Abbo LM, MacDougall C, Schuetz AN, Septimus EJ, Srinivasan A, Dellit TH, Falck-Ytter YT, Fishman NO, Hamilton CW, Jenkins TC, Lipsett PA, Malani PN, May LS, Moran GJ, Neuhauser MM, Newland JG, Ohl CA, Samore MH, Seo SK, Trivedi KK. Clin Infect Dis. 2016 May 15;62(10):e51-77. [PubMed]
  3. The Critical Role of the Staff Nurse in Antimicrobial Stewardship--Unrecognized, but Already There. Olans RN, Olans RD, DeMaria A Jr. Clin Infect Dis. 2016 Jan 1;62(1):84-9. [PubMed]
  4. New Horizons for Pediatric Antibiotic Stewardship. Goldman JL, Newland JG. Infect Dis Clin North Am. 2015 Sep;29(3):503-11. [PubMed]
  1. Safety and clinical outcomes of carbapenem de-escalation as part of an antimicrobial stewardship programme in an ESBL-endemic setting. Lew KY, Ng TM, Tan M, Tan SH, Lew EL, Ling LM, Ang B, Lye D, Teng CB. J Antimicrob Chemother 2014 Dec 3. [PubMed]
  2. The outcome of treating ESBL infections with carbapenems vs. non carbapenem antimicrobials. Trivedi M, Patel V, Soman R, Rodriguez C, Singhal T. J Assoc Physicians India 2012; 60: 28-30. [PubMed]
  3. Efficacy of empirical therapy with non-carbapenems for urinary tract infections with extended-spectrum beta-lactamase-producing Enterobacteriaceae. Asakura T, Ikeda M, Nakamura A, Kodera S. Int J Infect Dis 2014; 29C: 91-95. [PubMed] [Texto completo]
  4. Correlation between carbapenem consumption and antimicrobial resistance rates of Acinetobacter baumannii in a university-affiliated hospital in China. Cao J, Song W, Gu B, Mei YN, Tang JP, Meng L, Yang CQ, Wang H, Zhou H. J Clin Pharmacol 2013; 53: 96-102. [PubMed]
  5. Carbapenem stewardship: positive impact on hospital ecology. Lima AL, Oliveira PR, Paula AP, Dal-Paz K, Almeida JN Jr, Félix Cda S, Rossi F. Braz J Infect Dis 2011; 15: 1-5. [PubMed]
  6. Relationship of carbapenem restriction in 22 university teaching hospitals to carbapenem use and carbapenem-resistant Pseudomonas aeruginosa. Pakyz AL, Oinonen M, Polk RE. Antimicrob Agents Chemother 2009; 53: 1983-1986. [PubMed] [Texto completo]
  1. Antifungal stewardship in invasive Candida infections. Ruhnke M. Clin Microbiol Infect. 2014; 20 Suppl 6: 11-18. [PubMed]
  2. Evaluation of antifungal use in a tertiary care institution antifungal stewardship urgently needed. Valerio M, Rodriguez-Gonzalez CG, Muñoz P, Caliz B, Sanjurjo M, Bouza E; COMIC Study Group (Collaborative Group on Mycoses). J Antimicrob Chemother 2014; 69: 1993-1999. [PubMed]
  3. Improving the management of candidemia through antimicrobial stewardship interventions. Reed EE, West JE, Keating EA, Pancholi P, Balada-Llasat JM, Mangino JE, Bauer KA, Goff DA. Diagn Microbiol Infect Dis 2014; 78: 157-161. [PubMed]
  4. A non-compulsory stewardship programme for the management of antifungals in a university-affiliated hospital. López-Medrano F, San Juan R, Lizasoain M, Catalán M, Ferrari JM, Chaves F, Lumbreras C, Montejo JC, Herreros de Tejada A, Aguado JM. Clin Microbiol Infect 2013; 19: 56-61. [PubMed]
  5. Evaluation of antifungal therapy in patients with candidaemia based on susceptibility testing results: implications for antimicrobial stewardship programmes. Shah DN, Yau R, Weston J, Lasco TM, Salazar M, Palmer HR, Garey KW. J Antimicrob Chemother 2011; 66: 2146-2151. [PubMed] [Texto completo]

No hay comentarios:

Publicar un comentario